Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

ClinicalTrials.gov ID: NCT02987257

Public ClinicalTrials.gov record NCT02987257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of supportive care deemed to be the current standard of care. We will leverage the opportunity of this controlled design to collect multiples samples with an aim to discover new genetic and biological markers for prevention and early diagnosis and define cellular and molecular mechanisms to facilitate discovery of promising treatment strategies. This study has been preceded by a planning phase to ensure testing and development of harmonized supportive care infrastructure and operating procedures across sites.

Study identification

NCT ID
NCT02987257
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
2 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 20, 2023
Primary completion
Oct 30, 2025
Completion
Oct 30, 2025
Last update posted
Dec 16, 2025

2023 – 2025

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Valleywise Health Medical Center Phoenix Arizona 85008
University of California, Davis Medical Center Sacramento California 95817
MedStar Washington Hospital Center Washington D.C. District of Columbia 20010
University of Florida Health Burn Center Gainesville Florida 32610
University of Miami, Ryder Trauma Center Miami Florida 33136
Emory University at Grady Memorial Hospital Atlanta Georgia 30303
Loyola University Medical Center Maywood Illinois 60153
Johns Hopkins Bayview Medical Center Baltimore Maryland 21224
Wayne State University Detroit Michigan 48201
University of Tennessee Health Sciences Center Memphis Tennessee 38103
Vanderblt University Medical Center Nashville Tennessee 37232
University of Texas Southwestern Medical Center Dallas Texas 75390
University of Texas Medical Branch Galveston Texas 77555
University of Washington, Harborview Medical Center Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02987257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02987257 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →